Endocrinopathies Associated with Immune Checkpoint Inhibitor Cancer Treatment: A Review
| العنوان: | Endocrinopathies Associated with Immune Checkpoint Inhibitor Cancer Treatment: A Review |
|---|---|
| المؤلفون: | Mai Asano, Masahiro Iwasaku, Naoko Okura, Yoshiko Kaneko, Yoshie Morimoto, Tadaaki Yamada, Junji Uchino, Michiaki Fukui, Koichi Takayama |
| المصدر: | Journal of Clinical Medicine Journal of Clinical Medicine, Vol 9, Iss 2033, p 2033 (2020) |
| بيانات النشر: | MDPI AG, 2020. |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | Immune checkpoint inhibitors, tumor-bearing patients, lcsh:Medicine, 030209 endocrinology & metabolism, Review, Pembrolizumab, Bioinformatics, immune checkpoint inhibitors, 03 medical and health sciences, 0302 clinical medicine, medicine, Endocrine system, endocrine disorders, Lung cancer, Adverse effect, business.industry, lcsh:R, Thyroid, Cancer, General Medicine, medicine.disease, medicine.anatomical_structure, 030220 oncology & carcinogenesis, immune-related adverse events, Nivolumab, business |
| الوصف: | Treatment with immune checkpoint inhibitors has shown efficacy against a variety of cancer types. The effects of nivolumab and pembrolizumab on lung cancer have been reported, and further therapeutic advances are ongoing. The side effects of immune checkpoint inhibitors are very different from those of conventional cytocidal anticancer drugs and molecular targeted drugs, and they involve various organs such as the digestive and respiratory organs, thyroid and pituitary glands, and skin. The generic term for such adverse events is immune-related adverse events (irAEs). They are relatively infrequent, and, if mild, treatment with immune checkpoint inhibitors can be continued with careful control. However, early detection and appropriate treatment are critical, as moderate-to-severe irAEs are associated with markedly reduced organ function and quality of life, with fatal consequences in some cases. Of these, endocrinopathies caused by immune checkpoint inhibitors are sometimes difficult to distinguish from nonspecific symptoms in patients with advanced cancer and may have serious outcomes when the diagnosis is delayed. Therefore, it is necessary to anticipate and appropriately address the onset of endocrinopathies during treatment with immune checkpoint inhibitors. Here, we present a review of endocrine disorders caused by immune checkpoint inhibitor treatment. |
| تدمد: | 2077-0383 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0bafac8144d3214fb0eaf84bc6c8d792Test https://doi.org/10.3390/jcm9072033Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....0bafac8144d3214fb0eaf84bc6c8d792 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 20770383 |
|---|